Immunoscape
Singapore, SG · Founded 2016 · 22 employees on LinkedIn · 1 known investors
ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.
Founders & leadership
Immunoscape was founded in 2016 by Michael Fehlings, PhD, Evan Newell, PhD, and Alessandra Nardin, DVM.
MF
Michael Fehlings, PhDCo-founder, Chief Executive Officer
EN
Evan Newell, PhDCo-founder/Advisor
AN
Alessandra Nardin, DVMCo-founder, Vice President Strategy
Investors · 1
Frequently asked questions
- What does Immunoscape do?
- ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.
- Who founded Immunoscape?
- Immunoscape was founded by Michael Fehlings, PhD, Evan Newell, PhD, Alessandra Nardin, DVM in 2016.
- Who are Immunoscape's investors?
- Immunoscape's investors include Anzu Partners.
- Where is Immunoscape headquartered?
- Immunoscape is headquartered in Singapore, SG.